Tafinlar Liên Minh Châu Âu - Tiếng Hungary - EMA (European Medicines Agency)

tafinlar

novartis europharm limited - dabrafenib mesilate - melanóma - daganatellenes szerek - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 és 5. adjuváns kezelés melanomadabrafenib kombinálva trametinib jelzi adjuváns kezelésére felnőtt betegek színpad iii melanoma a braf v600 mutáció, a következő teljes resectio. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.